# Study Evaluating Sirolimus in Kidney Transplant Recipients.

> **NCT00167947** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 150 (estimated)

## Conditions studied

- Kidney Failure
- Graft vs Host Disease

## Interventions

- **DRUG:** Cyclosporine
- **DRUG:** Steroids
- **DRUG:** Rapamune (Sirolimus)

## Key facts

- **NCT ID:** NCT00167947
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2008-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00167947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00167947, "Study Evaluating Sirolimus in Kidney Transplant Recipients.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00167947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*